Technical Analysis for ASRT - Assertio Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 3.43 0.88% 0.03
ASRT closed up 0.88 percent on Friday, May 24, 2019, on 49 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ASRT trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 0.88%
1,2,3 Retracement Bearish Bearish Swing Setup 0.88%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.88%
Wide Bands Range Expansion 0.88%
Oversold Stochastic Weakness 0.88%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%

Older signals for ASRT ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
Pharmaceutical Pain Organ Systems Chemical Compounds Organic Compounds Analgesics Migraine Treatment Of Migraine Diabetic Peripheral Neuropathy Diclofenac Postherpetic Neuralgia
Is ASRT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.48
52 Week Low 3.085
Average Volume 981,174
200-Day Moving Average 4.9937
50-Day Moving Average 4.51
20-Day Moving Average 4.0985
10-Day Moving Average 3.653
Average True Range 0.2867
ADX 34.31
+DI 9.8006
-DI 32.011
Chandelier Exit (Long, 3 ATRs ) 4.0599
Chandelier Exit (Short, 3 ATRs ) 3.9451
Upper Bollinger Band 5.1527
Lower Bollinger Band 3.0443
Percent B (%b) 0.18
BandWidth 51.443211
MACD Line -0.3232
MACD Signal Line -0.2393
MACD Histogram -0.0839
Fundamentals Value
Market Cap 216.05 Million
Num Shares 63 Million
EPS -1.79
Price-to-Earnings (P/E) Ratio -1.92
Price-to-Sales 0.75
Price-to-Book 1.50
PEG Ratio 0.46
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.71
Resistance 3 (R3) 3.71 3.62 3.66
Resistance 2 (R2) 3.62 3.55 3.62 3.65
Resistance 1 (R1) 3.53 3.51 3.58 3.52 3.63
Pivot Point 3.44 3.44 3.46 3.44 3.44
Support 1 (S1) 3.34 3.37 3.39 3.34 3.23
Support 2 (S2) 3.25 3.32 3.25 3.21
Support 3 (S3) 3.16 3.25 3.20
Support 4 (S4) 3.15